logo
  

LogMeIn Q3 Profit Tops Estimates; Increases Q4 & FY14 Guidance - Quick Facts

LogMeIn, Inc. (LOGM) reported third-quarter net income of $2.3 million, or $0.09 per share, compared to a GAAP net loss of $56 thousand, or breakeven per share, prior year. Non-GAAP net income for the third quarter of 2014 was $8.1 million, or $0.32 per share.

Adjusted EBITDA for the third quarter of 2014 was $13.3 million, compared to $9.2 million, in the third quarter of 2013.

On average, nine analysts polled by Thomson Reuters expected the company to report profit per share of $0.28 for the quarter. Analysts' estimates typically exclude special items.

Total revenue increased to $58.1 million from $43.0 million. Analysts expected revenue of $56.34 million for the quarter.

LogMeIn announced that its Board has approved a $75 million share repurchase program. The company currently expects to fund the share repurchase program from its cash balances.

LogMeIn expects fourth-quarter revenue to be in the range of $58.4 million to $58.9 million. Adjusted EBITDA is expected to be in the range of $13.4 million to $13.8 million. Non-GAAP EPS is expected to be in the range of $0.32 to $0.33. The company expects GAAP EPS in the range of $0.04 to $0.05. Analysts expect the company to report fourth-quarter profit per share of $0.30 on revenue of $57.27 million.

The company expects full year 2014 revenue to be in the range of $220.5 million to $221.0 million. Adjusted EBITDA is expected to be in the range of $48.0 million to $48.4 million. Non-GAAP EPS is expected to be in the range of $1.15 to $1.16. The company expects GAAP EPS in the range of $0.22 to $0.23. Analysts expect the company to report full year profit per share of $1.09 on revenue of $217.55 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT